Latest Orphan drugs Stories
SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S.
The global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013.
-- Study Focused on Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Who are EphA3 Positive -- SOUTH SAN FRANCISCO, Calif., Feb.
Robust Clinical Data on Filanesib Presented at ASH Supporting Announced Registration Program BOULDER, Colo., Feb. 4, 2014 /PRNewswire/ -- Array BioPharma Inc.
Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912.
Data from Three Ongoing Phase II Trials of Pracinostat Anticipated by Year End SAN DIEGO, Jan. 14, 2014 /PRNewswire/ -- MEI Pharma, Inc.
In response to an article published by Medical News Today (MNT), Voices Against Brain Cancer discusses a new brain tumor vaccine that is personalized to each patient. New
ResearchMoz.us include new market research report " Global and China Monoclonal Antibody Industry Report, 2013 - 2017 " to its huge collection of research reports.